Withdrawal from TREVICTA^® was associated with delayed time to relapse relative to that of INVEGA SUSTENNA^® or oral paliperidone

Adapted from Weiden P et al. 2017.
^* Values shown for estimated median time to relapse correspond to the time since patients were randomised onto placebo following being symptomatically stable on either oral paliperidone ER, INVEGASUSTENNA^® or TREVICTA^® during the open-label phase.⁵

ER, extended release.
i. Patients who are adequately treated with 1-monthly paliperidone palmitate injectable (preferably for four months or more) and do not require dose adjustment may be switched to 3-monthly paliperidone palmitate
injection.²

This is a post hoc exploratory analysis to compare times to first relapse in adults with schizophrenia after double-blind discontinuation from ORAL paliperidone, once-monthly paliperidone palmitate (PP1M), or once-every-3-months paliperidone palmitate (PP3M).⁵
This analysis used data from similarly designed, randomized, double-blind, placebo-controlled, relapse prevention studies with ORAL paliperidone, PP1M, and PP3M.⁵
Briefly, men and women aged 18–65 years (≤ 70 years in the PP3M trial) were eligible if they had a schizophrenia diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), criteria for ≥ 1 year before screening.⁵

References
1. INVEGA^® Ministry of Health approved leaflet, 18/3/2019.
2. Risperdal^® Ministry of Health approved leaflet, 16/12/2019.
3. INVEGA SUSTENNA^® Ministry of Health approved leaflet, 18/3/2019.
4. TREVICTA^® Ministry of Health approved leaflet.19/5/2019.
5. Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. J Clin Psychiatry. 2017;78(7):e813-e820.

CP-253621